EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals Inc.
WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
8,99 €
4,45 %
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $22.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $31.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $31.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Mizuho. They set a "buy" rating and a $20.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $27.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at HC Wainwright from $25.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Mizuho from $20.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $44.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $35.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $35.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Mizuho from $30.00 to $39.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Mizuho from $39.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Chardan Capital from $39.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Nio Inc. diskutieren, NIO Inc. ADR